Clearwater International Spain advises Grupo Probelte on the sale of Probelte Biotech to Euromed

Clearwater International Spain has advised developer of nutrition and plant health products, Grupo Probelte on the sale of its Biotech portfolio Probelte Biotecnología to private equity backed Euromed.

Probelte Biotecnología, a subsidiary of Probelte Pharma, is dedicated to the production of natural extracts and biological pharmaceutical products and operates an extract factory with the largest production capacity in Spain. Its two main products are Mediteanox®, an olive extract with the highest concentration of Hydroxytyrosol on the market, and Pomanox®, a natural extract obtained from fresh pomegranate fruits.

Euromed, owned by the Riverside Private Equity fund, is also based in Spain. It is a leading producer of natural bioactive ingredients for the pharmaceutical, cosmetic and food supplement markets.

The Clearwater International team was led by Partner Francisco Gomez, with support from Director Vicente Orts Bañón and Associate Director Laura Arteche.

[quote name="Francisco Gómez, Partner, Clearwater International"]"This add-on will boost Euromed’s production capabilities and will convey new products to Euromed’s domestic and international markets.”[/quote]

Clearwater International has advised Probelte Pharma in the sales process. In addition to this transaction, Clearwater International’s Spanish Food & Beverage team has completed other transactions in this sub-sector including: Iberchem’s MBO, the purchase of Nutrafur by Frutarom, Secna’s MBO as well as the purchase of Tecno Bakery by Lesaffre.